226 related articles for article (PubMed ID: 34015728)
1. Non-clear cell renal carcinomas: Review of new molecular insights and recent clinical data.
Barthélémy P; Rioux-Leclercq N; Thibault C; Saldana C; Borchiellini D; Chevreau C; Desmoulins I; Gobert A; Hilgers W; Khalil A; Lemoine N; Schlürmann-Constans F; Négrier S
Cancer Treat Rev; 2021 Jun; 97():102191. PubMed ID: 34015728
[TBL] [Abstract][Full Text] [Related]
2. Advances in non-clear cell renal cell carcinoma management: From heterogeneous biology to treatment options.
Wilson NR; Acikgoz Y; Hasanov E
Int J Cancer; 2024 Mar; 154(6):947-961. PubMed ID: 37823185
[TBL] [Abstract][Full Text] [Related]
3. Targeted therapies and the treatment of non-clear cell renal cell carcinoma.
Bellmunt J; Dutcher J
Ann Oncol; 2013 Jul; 24(7):1730-1740. PubMed ID: 23625974
[TBL] [Abstract][Full Text] [Related]
4. Non-clear cell renal cell carcinoma: does the mammalian target of rapamycin represent a rational therapeutic target?
Albiges L; Molinie V; Escudier B
Oncologist; 2012; 17(8):1051-62. PubMed ID: 22807514
[TBL] [Abstract][Full Text] [Related]
5. Comprehensive Analysis of Survival Outcomes in Non-Clear Cell Renal Cell Carcinoma Patients Treated in Clinical Trials.
de Velasco G; McKay RR; Lin X; Moreira RB; Simantov R; Choueiri TK
Clin Genitourin Cancer; 2017 Dec; 15(6):652-660.e1. PubMed ID: 28410911
[TBL] [Abstract][Full Text] [Related]
6. Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial.
Barata PC; Chehrazi-Raffle A; Allman KD; Asnis-Alibozek A; Kasturi V; Pal SK
Oncologist; 2023 Oct; 28(10):894-900. PubMed ID: 37315114
[TBL] [Abstract][Full Text] [Related]
7. Advanced nccRCC: what therapeutic options in 2022?
Bigot C; Boudier P; Ladoire S; Barthélémy P
Bull Cancer; 2022 May; 109(2S):2S39-2S46. PubMed ID: 35760469
[TBL] [Abstract][Full Text] [Related]
8. Non-Clear Cell Renal Cell Carcinoma - Pathology and Treatment Options.
Ahrens M; Scheich S; Hartmann A; Bergmann L;
Oncol Res Treat; 2019; 42(3):128-135. PubMed ID: 30799404
[TBL] [Abstract][Full Text] [Related]
9. Common and uncommon histologic subtypes of renal cell carcinoma: imaging spectrum with pathologic correlation.
Prasad SR; Humphrey PA; Catena JR; Narra VR; Srigley JR; Cortez AD; Dalrymple NC; Chintapalli KN
Radiographics; 2006; 26(6):1795-806; discussion 1806-10. PubMed ID: 17102051
[TBL] [Abstract][Full Text] [Related]
10. Navigating the Current Landscape of Non-Clear Cell Renal Cell Carcinoma: A Review of the Literature.
John A; Spain L; Hamid AA
Curr Oncol; 2023 Jan; 30(1):923-937. PubMed ID: 36661719
[TBL] [Abstract][Full Text] [Related]
11. Advanced Non-Clear Cell Kidney Cancer: In Search of Rational Treatment Approaches.
Ornstein MC; Hutson TE
Cancer J; 2020; 26(5):441-447. PubMed ID: 32947312
[TBL] [Abstract][Full Text] [Related]
12. Metastatic non-clear cell renal cell carcinoma: current therapeutic options.
Schrader AJ; Olbert PJ; Hegele A; Varga Z; Hofmann R
BJU Int; 2008 Jun; 101(11):1343-5. PubMed ID: 18241246
[TBL] [Abstract][Full Text] [Related]
13. Chemotherapy for non-clear-cell renal cell carcinoma.
David KA; Milowsky MI; Nanus DM
Clin Genitourin Cancer; 2006 Mar; 4(4):263-8. PubMed ID: 16729909
[TBL] [Abstract][Full Text] [Related]
14. Molecular pathways in renal cell carcinoma: recent advances in genetics and molecular biology.
Su D; Singer EA; Srinivasan R
Curr Opin Oncol; 2015 May; 27(3):217-23. PubMed ID: 25811348
[TBL] [Abstract][Full Text] [Related]
15. Start of a New Era: Management of Non-Clear Cell Renal Cell Carcinoma in 2022.
Maughan BL
Curr Oncol Rep; 2022 Sep; 24(9):1201-1208. PubMed ID: 35438388
[TBL] [Abstract][Full Text] [Related]
16. The role of immunotherapy treatment in non-clear cell renal cell carcinoma: An analysis of the literature.
Ventriglia J; Passarelli A; Pisano C; Cecere SC; Rossetti S; Feroce F; Forte M; Casartelli C; Tambaro R; Pignata S; Perversi F; Di Napoli M
Crit Rev Oncol Hematol; 2023 Aug; 188():104036. PubMed ID: 37263397
[TBL] [Abstract][Full Text] [Related]
17. [Update on the different histological types of renal cell carcinoma and their specific treatment].
Neuzillet Y; Rioux-Leclercq N; Escudier B
Prog Urol; 2011 Mar; 21 Suppl 2():S23-6. PubMed ID: 21397823
[TBL] [Abstract][Full Text] [Related]
18. Immune checkpoint inhibitors in non-conventional histologies of renal-cell carcinoma.
Bersanelli M; Rebuzzi SE; Roviello G; Catalano M; Brunelli M; Rizzo M
Hum Vaccin Immunother; 2023 Dec; 19(1):2171672. PubMed ID: 36758960
[TBL] [Abstract][Full Text] [Related]
19. Management of Atypical Renal Cell Carcinomas.
Liaw BC; Mehrazin R; Baker C; Sfakianos JP; Tsao CK
Curr Treat Options Oncol; 2017 Sep; 18(10):61. PubMed ID: 28913767
[TBL] [Abstract][Full Text] [Related]
20. [Non clear cell renal cell carcinoma. 2008 update in renal tumor pathology].
Sibony M; Vieillefond A
Ann Pathol; 2008 Oct; 28(5):381-401. PubMed ID: 19068393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
